News
Genzyme’s Most Recent News
inv_genz_news Genzyme General News
| June 25, 2009 |
Genzyme Reports Progress Related to Allston Plant | | June 16, 2009 |
Genzyme Temporarily Interrupts Production at Allston Plant | | June 12, 2009 |
Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease | | June 2, 2009 |
Genzyme Completes Transaction with Bayer HealthCare | | May 29, 2009 |
Genzyme Receives Positive Opinion for European Approval of Mozobil | | May 21, 2009 |
Genzyme Submits All Information Requested by FDA for Lumizyme | | May 20, 2009 |
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint | | May 6, 2009 |
Genzyme Provides Outlook for Long-Term Growth at its Analyst Day Meeting | | April 22, 2009 |
Genzyme Reports Solid Financial Results for the First Quarter of 2009 | | March 31, 2009 |
Genzyme and Bayer HealthCare Enter New Strategic Agreement |
Genzyme News—One Year Archive >
Genzyme Financial News >
|
|
|
|
CONTACT INFORMATION: |
|
Genzyme Investor Relations
500 Kendall Street
Cambridge, MA 02142
T: 617 252 7500
Patrick Flanigan – 617 768 6563
Investor Information Line
U.S. T: 800 905 4369
Outside the U.S. T: 678 999 4572
Shareholder Contact
For questions about your shares, replacement of a lost stock certificate or a change of address call our transfer agent.
American Stock Transfer
59 Maiden Lane
New York, NY 10038
T: 212 936 5100
or
Genzyme Shareholder Services
T: 617 768 6686
|
|
|
|
Home
